A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT03505996 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 82
Last updated 2022-10-31
Summary
This is a multicenter, single-arm phase II study to evaluate the efficacy and safety of CS1001 monotherapy for relapsed/refractory classical Hodgkin Lymphoma (rr-cHL)
Conditions
Interventions
- BIOLOGICAL
-
CS1001
Monoclonal antibody
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-05-22
- Primary Completion
- 2020-02-19
- Completion
- 2021-11-01
Countries
- China
Study Locations
More Related Trials
-
Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma
NCT05900089 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
NCT00540007 ·Status: COMPLETED ·Phase: PHASE2
-
SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma
NCT05896046 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
NCT05293912 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
NCT05934513 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL
NCT05627856 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
NCT01393106 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
NCT06561425 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL
NCT07195799 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
NCT03220347 ·Status: TERMINATED ·Phase: PHASE1
-
Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
NCT03114683 ·Status: COMPLETED ·Phase: PHASE2
-
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
NCT06088654 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT04052997 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects
NCT04317885 ·Status: COMPLETED ·Phase: PHASE1
-
Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
NCT04510610 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
NCT01022996 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
NCT06845241 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma
NCT00413036 ·Status: COMPLETED ·Phase: PHASE2
-
CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
NCT05162976 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)
NCT05518318 ·Status: UNKNOWN ·Phase: PHASE3
-
Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs
NCT02597387 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
NCT05784441 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma
NCT04419441 ·Status: UNKNOWN
-
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
NCT02258555 ·Status: TERMINATED ·Phase: PHASE1
-
TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors
NCT05650580 ·Status: RECRUITING ·Phase: PHASE1